News

Novavax (NASDAQ:NVAX), known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP

Amentum (NYSE:AMTM), a leading provider of engineering, technical, and mission support services to government and commercial customers, reported results for Q3 FY2025 on August 5, 2025. The earnings

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP

Cumberland Pharmaceuticals (NASDAQ:CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology, released its financial results for the second quarter on

Orion Energy Systems (NASDAQ:OESX), a provider of energy-efficient LED lighting and electric vehicle (EV) charging solutions, released its results for the quarter ended June 30, 2025, on August 6

Ultragenyx Pharmaceutical (NASDAQ:RARE), a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street

MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from

UnitedHealth Group (NYSE: UNH) stock investors will want to digest this information before making the important decision to invest in or divest from this stock.

*Stock prices used were the

Geron (NASDAQ:GERN), a biotechnology company focused on therapies for blood disorders, released its second quarter 2025 results on August 6, 2025. The headline news was a sharp acceleration in

Evolus (NASDAQ:EOLS), a performance beauty company specializing in aesthetic neurotoxins and hyaluronic acid (HA) dermal fillers, reported Q2 2025 results on August 5, 2025. The headline news is a

Norwegian Cruise Line Holdings (NYSE: NCLH) benefited from a significant bump following earnings, rising 9% in the following trading session. With record revenue and strength in all three of its

I can actually think of multiple reasons to buy shares of Pfizer (NYSE: PFE) stock, but if I had to focus on only one, I'd choose its dividend. The stock's dividend yield was recently a whopping

Personalis (NASDAQ:PSNL), a precision genomics company focused on ultra-sensitive minimal residual disease (MRD) detection and comprehensive tumor profiling for cancer, reported its second-quarter

Vertex Pharmaceuticals (NASDAQ: VRTX) reported its second-quarter results after the market closed on Monday. Its shares plunged more than 17% in early trading on Tuesday.

Were Vertex's Q2 results

Advanced Micro Devices (NASDAQ:AMD), a leading semiconductor company best known for its processors and graphics cards, released its results on August 5, 2025. The quarter’s headline news was a

LeMaitre Vascular (NASDAQ:LMAT), a medical device company focused on vascular surgeons, reported its latest quarterly earnings after the bell on August 5, 2025. The company delivered GAAP results

QuidelOrtho (NASDAQ:QDEL), a global provider of diagnostic testing solutions, released its financial results for the quarter ended June 29, 2025, on August 5, 2025. The most notable headline was a

Esperion Therapeutics (NASDAQ:ESPR), a specialty pharmaceutical company focused on cardiovascular disease, delivered higher-than-expected GAAP results in its latest earnings release. On August 5

ImmunityBio (NASDAQ:IBRX), a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue (GAAP) jumped to $26.4 million, soundly beating

Halozyme Therapeutics (NASDAQ:HALO), a biotechnology company specializing in drug delivery innovations, released its second-quarter 2025 results on August 5, 2025. The quarter’s headline is

Ocular Therapeutix (NASDAQ:OCUL), a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant

Amgen (NASDAQ:AMGN), a leading biotechnology company with a wide portfolio of innovative medicines, released its second-quarter 2025 results on August 5, 2025. The headline news was a double-digit

Advanced Energy Industries (NASDAQ:AEIS), a global leader in precision power conversion solutions for the semiconductor, data center, industrial, and medical sectors, released its Q2 2025 earnings

Curis (NASDAQ:CRIS), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss